** Biotech company Humacyte's HUMA.O shares rise ~44.2% to $4.99 premarket
** HUMA, late on Thursday, said the U.S. FDA approved its implant Symvess for patients with extreme blood vessel injury
** The approval was based on clinical tests where Symvess showed high rates of blood flow and low rates of infection
** HUMA says the implant can be used as a channel in patients who need to have their blood flow restored to avoid imminent limb loss
** Up to last close, stock up 21.8% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。